Orionis to receive $105 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for the discovery of small-molecule monovale ...

HENDERSON, NV, USA I May 20, 2025 I Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated ...

SHANGHAI, China I May 20, 2025 I Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology ...

MUNICH, Germany I May 20, 2025 I Tubulis today announced that the first program from its strategic license agreement with Bristol Myers Squibb has entered ...

Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with ...

Pending data from the Phase 1 trial, Oruka plans to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026. The planned study design will evaluate the safety ...

BAY 3670549 is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor with potential to help control ...